Lab Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arthritis
Studies from ZymoGenetics, Inc. update current data on arthritis
May 18th, 2008
Fresh data on arthritis are presented in the report 'Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis.' "Atacicept is a recombinant fusion protein containing the extracellular ligand-binding portion of the transmembrane activator and CAML interactor (TACI, CD267) receptor and inhibits B lymphocyte stimulator (BLyS, CD257) and a proliferation-inducing ligand (APRIL, CD256), both potent stimulators of B cell maturation, proliferation, and survival. Atacicept pharmacokinetics and pharmacodynamics were assessed in a double-blind, placebo-controlled, phase I study in patients with active, moderate to severe rheumatoid arthritis receiving atacicept...
Source: Lab Business Week (2008-05-18)
|
